Optimizing combination treatment in the management of type 2 diabetes
Giuseppe Derosa, Salvadeo SibillaDepartment of Internal Medicine and Therapeutics University of Pavia, Pavia, ItalyAbstract: Obtaining the suggested glycemic control is the most important achievement in order to prevent cardiovascular complications in patients with type 2 diabetes. Monotherapy often...
Main Authors: | Giuseppe Derosa, Salvadeo Sibilla |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2007-11-01
|
Series: | Vascular Health and Risk Management |
Online Access: | https://www.dovepress.com/optimizing-combination-treatment-in-the-management-of-type-2-diabetes-peer-reviewed-article-VHRM |
Similar Items
-
Risk management in the treatment of type 2 diabetes with pioglitazone
by: Giuseppe Derosa, et al.
Published: (2009-07-01) -
Endothelial function, blood pressure control, and risk modification: impact of irbesartan alone or in combination
by: Giuseppe Derosa, et al.
Published: (2010-05-01) -
Patient considerations and clinical utility of a fixed dose combination of saxagliptin/metformin in the treatment of type 2 diabetes
by: Maffioli P, et al.
Published: (2011-06-01) -
Metabolic and antihypertensive effects of moxonidine and moxonidine plus irbesartan in patients withtype 2 diabetes mellitus and mild hypertension:a sequential, randomized, double-blind clinical trial
by: - Giuseppe Derosa, et al.
Published: (2009-03-01) -
Treatment update: thiazolidinediones in combination with metformin for the treatment of type 2 diabetes
by: John M Stafford, et al.
Published: (2007-09-01)